Viking Therapeutics
VKTX
Market cap $2.98B

26.57 USD

-1.17

4.22%

At close May 14, 4:00 PM EDT

After hours

26.30

-0.27

1.02%

1 day

-4.22%

5 days

-3.42%

1 month

8.14%

3 months

-12.83%

6 months

-50.40%

Year to date

-35.38%

1 year

-63.35%

5 years

285.07%

10 years

183.56%

About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Employees: 46

Healthcare Biotechnology

0

Funds holding %

of 7,425 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

80% more call options, than puts

Call options by funds: $296M | Put options by funds: $164M

15% more repeat investments, than reductions

Existing positions increased: 145 | Existing positions reduced: 126

6% less first-time investments, than exits

New positions opened: 81 | Existing positions closed: 86

1.09% less ownership

Funds ownership: 74.59% [Q3] → 73.51% (-1.09%) [Q4]

3% less funds holding

Funds holding: 418 [Q3] → 404 (-14) [Q4]

36% less capital invested

Capital invested by funds: $5.17B [Q3] → $3.3B (-$1.87B) [Q4]

75% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 2 (-6) [Q4]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$30

13%

upside

Avg. target

$83

211%

upside

High target

$104

291%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Cantor Fitzgerald Steven Seedhouse 0% 1-year accuracy 0 / 8 met price target	291%upside $104	Overweight Initiated	28 Apr 2025
Truist Securities Joon Lee 41% 1-year accuracy 17 / 41 met price target	182%upside $75	Buy Reiterated	28 Apr 2025
Morgan Stanley Michael Ulz 32% 1-year accuracy 6 / 19 met price target	284%upside $102	Overweight Maintained	24 Apr 2025
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 81 / 389 met price target	284%upside $102	Buy Reiterated	24 Apr 2025
Goldman Sachs Richard Law 45% 1-year accuracy 5 / 11 met price target	13%upside $30	Neutral Initiated	8 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 26 articles about VKTX published over the past 30 days

The Motley Fool

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years

Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns. However, with hundreds of companies vying for investors' attention, separating the wheat from the chaff can be challenging.

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years

The Motley Fool

3 Monster Stocks in the Making

Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.

3 Monster Stocks in the Making

The Motley Fool

Why Viking Therapeutics Stock Surged Nearly 20% Higher in April

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (VKTX 0.32%) stock in April.

Why Viking Therapeutics Stock Surged Nearly 20% Higher in April

The Motley Fool

Why Viking Therapeutics Stock Was Victorious This Week

Viking Therapeutics (VKTX 2.85%), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days, its price rose by almost 18%, according to data compiled by S&P Global Market Intelligence.

Why Viking Therapeutics Stock Was Victorious This Week

The Motley Fool

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

The Motley Fool

Where Will Viking Therapeutics Be in 3 Years?

The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug, sometimes referred to as a blockbuster, can build up a small developer into a mainstream competitor.

Where Will Viking Therapeutics Be in 3 Years?

The Motley Fool

1 Beaten-Down Stock to Buy and Hold for 10 Years

Viking Therapeutics (VKTX 3.44%) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of factors.

1 Beaten-Down Stock to Buy and Hold for 10 Years

The Motley Fool

Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual growth rate in the double digits from today over the next several years, with the market reaching $100 billion to $130 billion in the early 2030s.

Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain

The Motley Fool

Why Viking Therapeutics Stock Popped Again Today

Shares of Viking Therapeutics (VKTX 11.41%) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.

Why Viking Therapeutics Stock Popped Again Today

The Motley Fool

Why Viking Therapeutics Stock Popped Today

Viking Therapeutics (VKTX 0.40%) stock inched 2.3% higher through 10:20 a.m. ET Monday, and for a most curious reason.

Why Viking Therapeutics Stock Popped Today

See News Rankings

Charts implemented using Lightweight Charts™